Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Merck & Co. Win Conditional EU Nod for Rare Disease Drug in Children

06/22/2021 | 02:31am EDT


© MT Newswires 2021
All news about ASTRAZENECA PLC
07/30ASTRAZENECA : H1 2021 results
AQ
07/30ASTRAZENECA : NHS - Presidential visit strengthens healthcare partnership with K..
AQ
07/30ASTRAZENECA : US authorities probing Emergent BioSolutions over COVID-19 vaccine..
RE
07/30ASTRAZENECA : Shortages Hamper Ohangwena Vaccination Drive
AQ
07/30ASTRAZENECA : Receives a Buy rating from Credit Suisse
MD
07/29ASTRAZENECA : Emergent to resume J&J COVID-19 vaccine production at Baltimore pl..
RE
07/29Exclusive - AstraZeneca exploring options for COVID-19 vaccine business - exe..
RE
07/29AstraZeneca COVID-19 sales jump as drugmaker navigates vaccine challenges
RE
07/29ASTRAZENECA : to seek US approval of COVID vaccine in 2nd half
AQ
07/29ASTRAZENECA : COVID-19 Jabs Supplied to Canada, Mexico From US Before Inspection..
MT
More news
Financials (USD)
Sales 2021 34 636 M - -
Net income 2021 5 207 M - -
Net Debt 2021 26 467 M - -
P/E ratio 2021 30,4x
Yield 2021 2,45%
Capitalization 178 B 178 B -
EV / Sales 2021 5,90x
EV / Sales 2022 4,74x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 114,91 $
Average target price 133,75 $
Spread / Average Target 16,4%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC12.89%178 110
JOHNSON & JOHNSON9.42%453 313
ROCHE HOLDING AG13.38%337 105
PFIZER, INC.16.30%239 637
NOVARTIS AG0.28%225 343
ELI LILLY AND COMPANY44.22%221 348